Abstract
Purpose The regimens of weekly irinotecan with platinum have been used for treatment of metastatic small-cell lung cancer (SCLC). We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or extensive SCLC. Patients and Methods Eighty patients were enrolled with the following characteristics: 39 male patients, 41 female patients; median age, 65 years; and Zubrod performance status, 0 to 1 in 85% and 2 in 15% of patients. Dosing schemas were based on the maximum-tolerated dose derived in a previous phase I study. Chemotherapy-naive patients with extensive SCLC were treated with irinotecan 200 mg/m2 and carboplatin area under the curve (AUC) of 5 (arm A). Patients, who had previously been treated with chemotherapy and had relapsed disease received irinotecan 150 mg/m2 and carboplatin AUC of 5 (arm B). In each study arm, the treatment was given every 21 days for up to six cycles. Results The most common grade 3 to 4 toxicities included neutropenia (54%), thrombocytopenia (22%), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms. There were three treatment-related deaths owing to neutropenic sepsis. Among 72 assessable patients, response rates of 65% and 50% were observed, respectively, for arm A and arm B. The median survival for both study arms was identical at 10 months (95% CI, 6 to 14 months). A response rate of 65% was observed in the intracranial disease of 14 patients with known brain metastases. Conclusion This 21-day regimen of irinotecan and carboplatin seems promising for the treatment of relapsed SCLC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1401-1404 |
| Number of pages | 4 |
| Journal | Journal of Clinical Oncology |
| Volume | 27 |
| Issue number | 9 |
| DOIs | |
| State | Published - Mar 20 2009 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
- Medicine(all)
Cite this
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. / Lau, Derick H; Chen, Gigi; Huynh, Minh; Fehrenbacher, Lou; West, Howard; Lara, Primo N; Yavorkovsky, Leonid L.; Russin, Michael; Goldstein, Desiree; Gandara, David R.
In: Journal of Clinical Oncology, Vol. 27, No. 9, 20.03.2009, p. 1401-1404.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer
AU - Lau, Derick H
AU - Chen, Gigi
AU - Huynh, Minh
AU - Fehrenbacher, Lou
AU - West, Howard
AU - Lara, Primo N
AU - Yavorkovsky, Leonid L.
AU - Russin, Michael
AU - Goldstein, Desiree
AU - Gandara, David R
PY - 2009/3/20
Y1 - 2009/3/20
N2 - Purpose The regimens of weekly irinotecan with platinum have been used for treatment of metastatic small-cell lung cancer (SCLC). We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or extensive SCLC. Patients and Methods Eighty patients were enrolled with the following characteristics: 39 male patients, 41 female patients; median age, 65 years; and Zubrod performance status, 0 to 1 in 85% and 2 in 15% of patients. Dosing schemas were based on the maximum-tolerated dose derived in a previous phase I study. Chemotherapy-naive patients with extensive SCLC were treated with irinotecan 200 mg/m2 and carboplatin area under the curve (AUC) of 5 (arm A). Patients, who had previously been treated with chemotherapy and had relapsed disease received irinotecan 150 mg/m2 and carboplatin AUC of 5 (arm B). In each study arm, the treatment was given every 21 days for up to six cycles. Results The most common grade 3 to 4 toxicities included neutropenia (54%), thrombocytopenia (22%), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms. There were three treatment-related deaths owing to neutropenic sepsis. Among 72 assessable patients, response rates of 65% and 50% were observed, respectively, for arm A and arm B. The median survival for both study arms was identical at 10 months (95% CI, 6 to 14 months). A response rate of 65% was observed in the intracranial disease of 14 patients with known brain metastases. Conclusion This 21-day regimen of irinotecan and carboplatin seems promising for the treatment of relapsed SCLC.
AB - Purpose The regimens of weekly irinotecan with platinum have been used for treatment of metastatic small-cell lung cancer (SCLC). We conducted a multi-institution phase II trial to evaluate a novel 21-day schedule of irinotecan and carboplatin in patients with relapsed or extensive SCLC. Patients and Methods Eighty patients were enrolled with the following characteristics: 39 male patients, 41 female patients; median age, 65 years; and Zubrod performance status, 0 to 1 in 85% and 2 in 15% of patients. Dosing schemas were based on the maximum-tolerated dose derived in a previous phase I study. Chemotherapy-naive patients with extensive SCLC were treated with irinotecan 200 mg/m2 and carboplatin area under the curve (AUC) of 5 (arm A). Patients, who had previously been treated with chemotherapy and had relapsed disease received irinotecan 150 mg/m2 and carboplatin AUC of 5 (arm B). In each study arm, the treatment was given every 21 days for up to six cycles. Results The most common grade 3 to 4 toxicities included neutropenia (54%), thrombocytopenia (22%), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms. There were three treatment-related deaths owing to neutropenic sepsis. Among 72 assessable patients, response rates of 65% and 50% were observed, respectively, for arm A and arm B. The median survival for both study arms was identical at 10 months (95% CI, 6 to 14 months). A response rate of 65% was observed in the intracranial disease of 14 patients with known brain metastases. Conclusion This 21-day regimen of irinotecan and carboplatin seems promising for the treatment of relapsed SCLC.
UR - http://www.scopus.com/inward/record.url?scp=63049136369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63049136369&partnerID=8YFLogxK
U2 - 10.1200/JCO.2008.20.2127
DO - 10.1200/JCO.2008.20.2127
M3 - Article
C2 - 19204194
AN - SCOPUS:63049136369
VL - 27
SP - 1401
EP - 1404
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 9
ER -